由 Gus Iversen
, Editor in Chief | June 25, 2015
In partnership with Proton Partners International (PPI), IBA Group is bringing proton therapy to the U.K.
The three systems will all be pencil beam and cone beam CT capable ProteusONE solutions, and come with a ten-year maintenance contract.
A statement from IBA estimates the cost for those individual agreements to typically fall in the ballpark of 35 to 40 million euros.
Through an agreement signed last September, Philips has been appointed to deliver software and technology tools to the facilities, as well as big bore CT scanners.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
The facilities will be built in Newport and Newcastle, while the location of the third ProteusONE remains unannounced. The plans were initially set underway by PPI, private limited company in Wales with nearly 100 million euros in institutional and private investor equity finance.
"PPI's choice of IBA not only strengthens our world-leading position in proton therapy, but also demonstrates the preference of IBA as the most experienced proton therapy provider in the market and the fastest from signing to treatment," said Olivier Legrain, CEO of IBA, in a statement.
Before selecting IBA, it conducted an exhaustive selection process across two continents, including visiting the Willis Knighton Hospital in Shreveport, Louisiana to see an IBA treatment room in operation. Final selection was made on technical and commercial merit.
These facilities will mark the eighth, ninth, and tenth ProteusONE installations and are expected to ramp up in 2017.